Business
REGENXBIO Reports Second Quarter 2021 Financial Results and Operational Highlights
ROCKVILLE, Md., Aug. 9, 2021 /PRNewswire/ -- Enrollment in RGX-314 programs is on-track, including the pivotal program for the treatment of wet AMD utilizing
About this update from Regenxbio Inc.
[{"type":"text","content":"ROCKVILLE, Md., Aug. 9, 2021 /PRNewswire/ -- \nEnrollment in RGX-314 programs is on-track, including the pivotal program for the treatment of wet AMD utilizing subretinal delivery, and the Phase II trials for the treatment of wet AMD and DR utilizing in-office suprachoroidal delivery Interim data from RGX-314 Phase II trial for the treatment of wet AMD utilizing in-office suprachoroidal delivery will be presented at Retina Society 54th Annual Scientific Meeting Reported additional positive interim data in May 2021 from RGX-121 Phase I/II trial for the treatment of patients up to 5 years old with MPS II; enrollment continues in Cohort 3 at increased dose Expects to file IND for RGX-202 for the treatment of Duchenne by end of 2021 $593.0 million in cash, cash equivalents and marketable securities as of June 30, 2021 Conference call Monday, August 9th at 4:30 p.m. ETREGENXBIO Inc. (Nasdaq: RGNX) today announced financial results for the second quarter ended June 30, 2021, and recent operational highlights.\n\"We are well positioned to expand upon the progress we have made in our gene therapy programs over the first half of 2021, including clinical advancements in our RGX-314 programs for the treatment of wet AMD and diabetic retinopathy,\" said Kenneth T. Mills, President and Chief Executive Officer of REGENXBIO. \"Earlier this year, we reported additional positive interim data from Cohorts 1 and 2 of our Phase I/II trial of RGX-121 in patients up to 5 years old with MPS II, which included safety, biomarker data, and emerging evidence of systemic enzyme expression and activity in urine and plasma. Patient enrollment in this program continues. In addition, we expect to submit an IND for RGX-202 for the treatment of patients with Duchenne by the end of 2021.\"\nRecent Operational Highlights\nGene Therapy Using NAV Vectors for AAV-Mediated Antibody Delivery\nPivotal Program for RGX-314 for the Treatment of Wet Age-related Macular Degeneration (wet AMD) Enrollment is ongoing in ATMOSPHERETM, the first of two planned pivotal trials to evaluate the efficacy and safety of RGX-314 in patients with wet AMD using the subretinal delivery approach. REGENXBIO is on-track to initiate the second pivotal trial in the fourth quarter of 2021.Suprachoroidal Delivery of RGX-314 for the Treatment of Wet AMD Interim data from Cohort 1 (dose level: 2.5x1...